Equities research analysts predict that Advaxis, Inc. (NASDAQ:ADXS) will report sales of $770,000.00 for the current fiscal quarter, Zacks Investment Research reports. Two analysts have issued estimates for Advaxis’ earnings. The highest sales estimate is $1.20 million and the lowest is $340,000.00. Advaxis reported sales of $1.75 million during the same quarter last year, which would suggest a negative year over year growth rate of 56%. The firm is scheduled to announce its next earnings report on Thursday, June 6th.
According to Zacks, analysts expect that Advaxis will report full-year sales of $21.72 million for the current year, with estimates ranging from $20.03 million to $23.40 million. For the next year, analysts anticipate that the business will report sales of $1.30 million. Zacks Investment Research’s sales averages are a mean average based on a survey of research analysts that follow Advaxis.
Advaxis (NASDAQ:ADXS) last announced its quarterly earnings data on Tuesday, March 12th. The biotechnology company reported $0.18 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.25) by $0.43. The company had revenue of $19.69 million for the quarter. Advaxis had a negative net margin of 140.12% and a negative return on equity of 101.51%.
A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Virtu Financial LLC lifted its stake in shares of Advaxis by 740.4% in the fourth quarter. Virtu Financial LLC now owns 176,213 shares of the biotechnology company’s stock worth $33,000 after buying an additional 155,246 shares during the last quarter. Two Sigma Investments LP lifted its stake in shares of Advaxis by 2,468.2% in the fourth quarter. Two Sigma Investments LP now owns 369,815 shares of the biotechnology company’s stock worth $70,000 after buying an additional 355,415 shares during the last quarter. Deutsche Bank AG lifted its stake in shares of Advaxis by 5,970.3% in the fourth quarter. Deutsche Bank AG now owns 562,294 shares of the biotechnology company’s stock worth $106,000 after buying an additional 553,031 shares during the last quarter. Renaissance Technologies LLC lifted its stake in shares of Advaxis by 173.0% in the third quarter. Renaissance Technologies LLC now owns 1,191,846 shares of the biotechnology company’s stock worth $1,120,000 after buying an additional 755,352 shares during the last quarter. Finally, BlackRock Inc. increased its position in Advaxis by 3.1% during the fourth quarter. BlackRock Inc. now owns 1,446,288 shares of the biotechnology company’s stock worth $275,000 after acquiring an additional 43,368 shares during the period.
Shares of Advaxis stock traded down $0.15 during trading on Friday, hitting $3.40. The stock had a trading volume of 15,940 shares, compared to its average volume of 1,181,754. The company has a market cap of $19.34 million, a P/E ratio of -0.18 and a beta of 3.95. Advaxis has a 1 year low of $2.70 and a 1 year high of $30.60.
Advaxis Company Profile
Advaxis, Inc, a late-stage biotechnology company, focuses on the discovery, development, and commercialization of Listeria monocytogenes (Lm) technology based antigen delivery product in the United States. It is developing therapies for HPV-related cancers using axalimogene filolisbac (AXAL) for the treatment of head and neck cancer.
Read More: Quiet Period Expirations
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Advaxis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Advaxis and related companies with MarketBeat.com's FREE daily email newsletter.